Clinical trial NCT02920632: Cognitive Training in Parkinson Study
Official title: COGTIPS (COGnitive Training In Parkinson Study): The Effect of Online Cognitive Training on Cognition and Brain Networks in Parkinson's Disease
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Parkinson Disease
Impaired Cognition
Alteration in Cognition
Keywords: Parkinson
Cognitive training
Cognitive rehabilitation
Brain networks
Lead sponsor: Amsterdam UMC, location VUmc
Sponsor class: OTHER
Collaborators: name: Dutch Parkinson Patient Association
First posted: 2016-09-30
Enrollment: 167
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the efficacy of an eight-week online cognitive training program on objective and subjective cognitive functions in Parkinson's disease. Moreover, we intend to map the effect on brain network function, and if cognitive training can prevent the development of PD-MCI/PD-D after one- and two-year follow-up. In this study, two training groups will be compared (N: 70 vs 70). In a part of the participants MRI will be assessed (N: 40 vs. 40). We expect cognitive training to improve cognitive functions, and to improve the efficiency of brain network function. Moreover, we expect that cognitive training can decrease the risk of PD-MCI/PD-D at one- and two-year follow-up.

Detailed description: BACKGROUND In Parkinson's disease (PD), cognitive dysfunction is frequently reported - approximately 50% of PD patients experience cognitive impairment (Litvan et al., 2011). Of these impairments, executive dysfunction is most frequently reported early in the disease trajectory (Bosboom, Stoffers, \& Wolters, 2004; Muslimovic, Post, Speelman, \& Schmand, 2005), while impairments in other cognitive domains (i.e. attention, episodic memory, visuospatial functions) are also highly prevalent (Bosboom et al., 2004). The majority of PD patients ultimately develops PD dementia (PD-D; Aarsland, Andersen, Larsen, Lolk, \& Kragh-Sorensen, 2003; Hely, Reid, Adena, Halliday, \& Morris, 2008). Moreover, about 10% of the PD patients develops PD-D every year (Aarsland \& Kurz, 2010). Cognitive dysfunctions in PD have a significant negative influence on the quality of life (Klepac, Trkulja, Relja, \& Babic, 2008), while treatment of these dysfunctions is in its infancy.

Cognitive training may provide a new intervention for reducing cognitive complaints and delaying the onset of mild cognitive impairment (MCI) or PD-D. This intervention has been widely studied in other diseases (Cicerone et al., 2011; Olazaran et al., 2010). Moreover, studies have provided evidence not only for behavioral influences, but also for brain connectivity and activity effects of cognitive training (Chapman et al., 2015; Castellanos et al., 2010; Subramaniam et al., 2012; Subramaniam et al., 2014; Belleville et al., 2011; Rosen, Sugiura, Kramer, Whitfield-Gabrieli, \& Gabrieli, 2011). This suggests a restorative effect of cognitive training on disrupted brain networks.

In PD, cognitive dysfunction - mainly executive dysfunction - is associated with disruption of the cortico-striato-thalamo-corticale circuits by depletion of dopamine. Dysfunction of these circuits seems to disrupt several cognitive networks, which leads to cognitive dysfunction (Baggio et al., 2014). Cognitive training could counteract these disruptions by normalising activity and connectivity, and ultimately lead to a reduction of impairment. Since earlier studies in different patient populations have shown that cognitive training has lasting effects (Petrelli et al., 2015), normalising disruptions underlying cognitive impairment could prevent cognitive deterioration and therefore prevent or delay the development of PD-D.

Few studies in PD have focused on cognitive training and its neural correlates. A meta-analysis by Leung et al. (2015) showed positive effects of cognitive training on mainly 'frontal' cognitive functions (i.e. working memory, executive functions, processing speed). In addition, earlier research has described a neuroprotective effect of cognitive training on the development of MCI in PD (odds ratio: 3; Petrelli et al., 2015). Until now, however, studies have been relatively small and mainly without a controlled design - consequently, there is a need for large randomized controlled studies (Hindle, Petrelli, Clare, \& Kalbe, 2013; Leung et al., 2015). Moreover, neural effects of cognitive training are largely unknown in PD. Furthermore, it is important to study the improvement of patients on daily functioning after cognitive training, rather than solely focusing on cognitive tasks and neural measures. Finally, cognitive training has been performed mainly in hospital settings, while PD patients have mobility problems - a training method suitable to perform from home is therefore needed for this population.

OBJECTIVES The study objective is primarily to measure the effect of an online cognitive training in patients with mild cognitive complaints in PD. An online training, specifically altered for PD patients (BrainGymmer) will be compared with an active comparator. In both conditions, participants will train eight weeks, three times a week during 45 minutes.

Primary objective:

- To measure the effect of an online cognitive training (as compared to the active comparator), eight weeks, three times a week, on executive functions in patients with mild cognitive complaints in PD.

Secondary objectives:

* To measure the effect of online cognitive training on daily functioning.
* To measure the endurance of the training effect after six months, one and two years.
* To assess the reduced risk of MCI and PD-D development by cognitive training.
* To assess the effect of cognitive training on brain network efficiency and connectivity.
* To assess the effect of cognitive training on brain network topology and connectivity, and cognition, relative to those of matched healthy control participants.
* To assess the difference in brain network topology and connectivity, and cognition, between Parkinson's disease patients with or without cognitive impairment and healthy control participants.

Eligibility criteria: --- Parkinson's disease patients ---

Inclusion Criteria:

* Subjective cognitive complaints, measured by the Parkinson's Disease Cognitive Functional Rating Scale score \> 3 (PD-CFRS). A score above 3 indicates significant cognitive complaints, that are milder than complaints associated with Parkinson's disease dementia. This questionnaire is filled in by the patient.
* Participants' Hoehn \& Yahr stage is lower than 4. Patients are stable on dopaminergic medication at least a month before starting the intervention. During the intervention, patient and neurologist will be asked to keep the dopaminergic medication dosage as stable as possible.
* Participants have access to a computer or tablet, with access to the Internet. If the participant uses a computer, he or she is capable of using a keyboard and computer mouse.
* Participants are willing to sign informed consent.

Exclusion Criteria:

General criteria:

* Indications for a dementia syndrome, measured by the Self-administered Gerocognitive Examination score \< 14 or the Montreal Cognitive Assessment score \< 22.
* Current drug- or alcohol abuse, measured by a score \> 1 on the four CAGE AID-questions (according to the Trimbos guidelines).
* The inability to undergo extensive neuropsychological assessment, or eight weeks of intervention.
* Moderate to severe depressive symptoms, as defined by the Beck Depression Inventory score \> 18.
* An impulse control disorder, including internet addiction, screened by the impulse control disorder criteria interview.
* Psychotic symptoms, screened by the Questionnaire for Psychotic Experiences. Benign hallucinations with insight are not contraindicated.
* Traumatic brain injury, only in case of a contusio cerebri with 1) loss of consciousness for \> 15 minutes and 2) posttraumatic amnesia \> 1 hour.
* A space occupying lesion defined by a radiologist, or significant vascular abnormalities (Fazekas \> 1).

For participation in MRI research:

* Severe claustrophobia
* Metal in the body (for example, deep brain stimulator or pacemaker)
* Pregnancy
* Problems with or shortness of breath during 60 minutes of lying still.

  * Healthy control subjects ---

Inclusion criteria:

- Participants are willing to sign informed consent.

Exclusion criteria:

* Indications for a neurological disease, such as Parkinson's disease, Alzheimer's disease, mild cognitive impairment, multiple sclerosis or Huntington's disease;
* Indications for a dementia syndrome, measured by the Montreal Cognitive Assessment score \< 22.
* Indications for a current stroke or CVA, or in the past.
* Indications for the presence of a psychotic or depressive disorder, measured with a positive screening on the SAPS-PD (benign hallucinations with insight are not contraindicated) and a BDI \> 18 respectively.
* Current drug- or alcohol abuse, measured by a score \> 1 on the four CAGE AID-questions (according to the Trimbos guidelines).
* The inability to undergo extensive neuropsychological assessment, or eight weeks of intervention.
* Traumatic brain injury, only in case of a contusio cerebri with 1) loss of conciousness for \> 15 minutes and 2) posttraumatic amnesia \> 1 hour.
* A space occupying lesion defined by a radiologist, or significant vascular abnormalities (Fazekas \> 1).
* Contra-indications for participation in MRI scanning (see above)

Primary outcomes:
measure: Accuracy on the Tower of London Task
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
Secondary outcomes:
measure: Total Score on Parkinson's Disease Cognitive Functional Rating Scale
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Total Score on Cognitive Failures Questionnaire
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Reaction Time on the Tower of London Task
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Performance on the Controlled Oral Word Association Test
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Performance on Tower of London Accuracy at Six-months Follow-up
timeFrame: Six months after training completion (T2)
measure: Performance on Tower of London Accuracy at One-year Follow-up
timeFrame: One year after completion of intervention (T3, "Follow-up 2")
measure: Performance on Tower of London Accuracy at Two-year Follow-up
timeFrame: Two years after completion of the intervention (T4)
measure: Conversion to Mild Cognitive Impairment or Dementia at One-year Follow-up
timeFrame: One year after completion of the intervention (T3)
measure: Performance on the Stroop Color-Word Test, Card I
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Performance on the Stroop Color-Word Test, Card III
timeFrame: Baseline (T0, "Pre-intervention") to eight weeks (T1, "Post-intervention")
measure: Conversion of Cognitive Status at Two-year Follow-up
timeFrame: Two year after completion of the intervention (T3)
Other outcomes:
measure: Difference Between Parkinson's Disease Patients' Brain Network Topology With or Without Cognitive Impairment, and Healthy Control Subjects.
timeFrame: Pre-intervention (T0)
measure: Online Cognitive Training Effect on Brain Network Topology Relative to Healthy Control Group
timeFrame: Eight weeks (T1)
measure: Online Cognitive Training Effect on Brain Activity Measured by Resting State fMRI
timeFrame: Eight weeks (T1)
measure: Online Cognitive Training Effect on Structural Brain Connectivity Measured by DTI
timeFrame: Eight weeks (T1)
measure: Online Cognitive Training Effect on Brain Morphology Measured by MRI
timeFrame: Eight weeks (T1)
measure: Age
timeFrame: Pre-intervention (T0)
measure: Sex
timeFrame: Pre-intervention (T0)
measure: Educational Level
timeFrame: Pre-intervention (T0)
measure: Disease Duration
timeFrame: Pre-intervention (T0)
measure: Disease Stage
timeFrame: Pre-intervention (T0), one year (T3), two years (T4)
measure: Medication Use
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Motor Symptoms
timeFrame: Pre-intervention (T0), one year (T3), two years (T4)
measure: Depressive Symptom Severity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Anxiety Symptom Severity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Impulse Control Disorder Symptom Severity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Psychotic Symptom Severity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Apathy Symptom Severity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Expectations of the Intervention
timeFrame: Pre-intervention (T0)
measure: Global Cognitive Functioning (1)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Global Cognitive Functioning (2)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Attention/Working Memory (1)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Attention/Working Memory (2)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Episodic Memory (1)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Episodic Memory (2)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Language (1)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Language (2)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Visuospatial/Visuoconstructive Function (1)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Specific Cognitive Functioning: Visuospatial/Visuoconstructive Function (2)
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Physical Activity
timeFrame: Pre-intervention (T0), eight weeks (T1), six months (T2), one year (T3), two years (T4)
measure: Cognitive Reserve
timeFrame: Two years (T4)
Locations:
city: Amsterdam
country: Netherlands
facility: VU University Medical Center
state: Noord-Holland
Study officials:
affiliation: Amsterdam UMC, location VUmc
name: Chris Vriend, PhD.
role: PRINCIPAL_INVESTIGATOR
affiliation: Amsterdam UMC, location VUmc
name: Odile A Van den Heuvel, MD PhD.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Litvan I, Aarsland D, Adler CH, Goldman JG, Kulisevsky J, Mollenhauer B, Rodriguez-Oroz MC, Troster AI, Weintraub D. MDS Task Force on mild cognitive impairment in Parkinson's disease: critical review of PD-MCI. Mov Disord. 2011 Aug 15;26(10):1814-24. doi: 10.1002/mds.23823. Epub 2011 Jun 9.
citation: Bosboom JL, Stoffers D, Wolters ECh. Cognitive dysfunction and dementia in Parkinson's disease. J Neural Transm (Vienna). 2004 Oct;111(10-11):1303-15. doi: 10.1007/s00702-004-0168-1. Epub 2004 Jun 30.
citation: Muslimovic D, Post B, Speelman JD, Schmand B. Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology. 2005 Oct 25;65(8):1239-45. doi: 10.1212/01.wnl.0000180516.69442.95.
citation: Aarsland D, Andersen K, Larsen JP, Lolk A, Kragh-Sorensen P. Prevalence and characteristics of dementia in Parkinson disease: an 8-year prospective study. Arch Neurol. 2003 Mar;60(3):387-92. doi: 10.1001/archneur.60.3.387.
citation: Hely MA, Reid WG, Adena MA, Halliday GM, Morris JG. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44. doi: 10.1002/mds.21956.
citation: Aarsland D, Kurz MW. The epidemiology of dementia associated with Parkinson disease. J Neurol Sci. 2010 Feb 15;289(1-2):18-22. doi: 10.1016/j.jns.2009.08.034. Epub 2009 Sep 4.
citation: Klepac N, Trkulja V, Relja M, Babic T. Is quality of life in non-demented Parkinson's disease patients related to cognitive performance? A clinic-based cross-sectional study. Eur J Neurol. 2008 Feb;15(2):128-33. doi: 10.1111/j.1468-1331.2007.02011.x.
citation: Cicerone KD, Langenbahn DM, Braden C, Malec JF, Kalmar K, Fraas M, Felicetti T, Laatsch L, Harley JP, Bergquist T, Azulay J, Cantor J, Ashman T. Evidence-based cognitive rehabilitation: updated review of the literature from 2003 through 2008. Arch Phys Med Rehabil. 2011 Apr;92(4):519-30. doi: 10.1016/j.apmr.2010.11.015.
citation: Olazaran J, Reisberg B, Clare L, Cruz I, Pena-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muniz R. Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord. 2010;30(2):161-78. doi: 10.1159/000316119. Epub 2010 Sep 10.
citation: Chapman SB, Aslan S, Spence JS, Hart JJ Jr, Bartz EK, Didehbani N, Keebler MW, Gardner CM, Strain JF, DeFina LF, Lu H. Neural mechanisms of brain plasticity with complex cognitive training in healthy seniors. Cereb Cortex. 2015 Feb;25(2):396-405. doi: 10.1093/cercor/bht234. Epub 2013 Aug 28.
citation: Castellanos NP, Paul N, Ordonez VE, Demuynck O, Bajo R, Campo P, Bilbao A, Ortiz T, del-Pozo F, Maestu F. Reorganization of functional connectivity as a correlate of cognitive recovery in acquired brain injury. Brain. 2010 Aug;133(Pt 8):2365-81. doi: 10.1093/brain/awq174.
citation: Subramaniam K, Luks TL, Fisher M, Simpson GV, Nagarajan S, Vinogradov S. Computerized cognitive training restores neural activity within the reality monitoring network in schizophrenia. Neuron. 2012 Feb 23;73(4):842-53. doi: 10.1016/j.neuron.2011.12.024.
citation: Subramaniam K, Luks TL, Garrett C, Chung C, Fisher M, Nagarajan S, Vinogradov S. Intensive cognitive training in schizophrenia enhances working memory and associated prefrontal cortical efficiency in a manner that drives long-term functional gains. Neuroimage. 2014 Oct 1;99:281-92. doi: 10.1016/j.neuroimage.2014.05.057. Epub 2014 May 24.
citation: Belleville S, Clement F, Mellah S, Gilbert B, Fontaine F, Gauthier S. Training-related brain plasticity in subjects at risk of developing Alzheimer's disease. Brain. 2011 Jun;134(Pt 6):1623-34. doi: 10.1093/brain/awr037. Epub 2011 Mar 22.
citation: Rosen AC, Sugiura L, Kramer JH, Whitfield-Gabrieli S, Gabrieli JD. Cognitive training changes hippocampal function in mild cognitive impairment: a pilot study. J Alzheimers Dis. 2011;26 Suppl 3(Suppl 3):349-57. doi: 10.3233/JAD-2011-0009.
citation: Baggio HC, Sala-Llonch R, Segura B, Marti MJ, Valldeoriola F, Compta Y, Tolosa E, Junque C. Functional brain networks and cognitive deficits in Parkinson's disease. Hum Brain Mapp. 2014 Sep;35(9):4620-34. doi: 10.1002/hbm.22499. Epub 2014 Mar 17.
citation: Petrelli A, Kaesberg S, Barbe MT, Timmermann L, Rosen JB, Fink GR, Kessler J, Kalbe E. Cognitive training in Parkinson's disease reduces cognitive decline in the long term. Eur J Neurol. 2015 Apr;22(4):640-7. doi: 10.1111/ene.12621. Epub 2014 Dec 22.
citation: Leung IH, Walton CC, Hallock H, Lewis SJ, Valenzuela M, Lampit A. Cognitive training in Parkinson disease: A systematic review and meta-analysis. Neurology. 2015 Nov 24;85(21):1843-51. doi: 10.1212/WNL.0000000000002145. Epub 2015 Oct 30.
citation: Hindle JV, Petrelli A, Clare L, Kalbe E. Nonpharmacological enhancement of cognitive function in Parkinson's disease: a systematic review. Mov Disord. 2013 Jul;28(8):1034-49. doi: 10.1002/mds.25377. Epub 2013 Feb 20.
citation: van Balkom TD, Berendse HW, van der Werf YD, Twisk JWR, Zijlstra I, Hagen RH, Berk T, Vriend C, van den Heuvel OA. COGTIPS: a double-blind randomized active controlled trial protocol to study the effect of home-based, online cognitive training on cognition and brain networks in Parkinson's disease. BMC Neurol. 2019 Jul 31;19(1):179. doi: 10.1186/s12883-019-1403-6.